Peg-IFN-alpha agents have been included in the 2009 National Reimbursement Drug List in China, with a reimbursement rate that ranges from 50 to 90 percent and varies by region.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”